Author

Elaine B. Cadogan

AstraZeneca (United Kingdom)ORCID 0000-0002-9757-8305Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:CRISPR screen· 1 Research Focus:perturbation response prediction· 1 Organism:rat· 1

Frequent Co-Authors

Aaron SmithiD· 1 shared Alan Lau· 1 shared Amir Taheri‐GhahfarokhiiD· 1 shared Anders LundiniD· 1 shared Anderson T. WangiD· 1 shared Andres Tellez· 1 shared Bastian SchiffthaleriD· 1 shared Björn Magnusson· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron SmithORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Gap scheduling of a PARP inhibitor and nanoparticle TOP1 agent combination avoids synergistic bone marrow toxicity

Lenka Oplustil O’Connor, Anderson T. Wang, Claire Sadler, Jennifer Barnes, Rajesh Odedra, Aaron Smith, Gareth Hughes, Alan Lau, Andres Tellez, Scott D. Eliasof, Elaine B. Cadogan, Mark J. O’Connor

The paper identifies a gap schedule for combining a PARP inhibitor and a tumor-targeted nanoparticle chemotherapy to enhance efficacy while reducing bone marrow toxicity.

bioRxiv · Apr 30, 2025 · PreprintCancer Biology

Simultaneous inhibition of DNA-PK and Pol{Theta} improves integration efficiency and precision of genome editing

Sandra Wimberger, Nina Akrap, Mike A. Firth, Johan Brengdahl, Susanna Engberg, Marie K. Schwinn, Michael R. Slater, Anders Lundin, Pei-Pei Hsieh, Songyuan Li, Silvia Cerboni, Jonathan Sumner, Burcu Bestas, Bastian Schiffthaler, Björn Magnusson, , Marcello Maresca

This study identifies AZD7648 and Pol{Theta} inhibitors as a combination (2iHDR) that enhances CRISPR-Cas9 integration efficiency and precision by targeting DNA-PK and MMEJ repair pathways.

Nature Communications · Aug 14, 2023Peer-reviewedMolecular Biology